Search results
Results from the WOW.Com Content Network
Sanofi was founded in 15 February 1973 [5] as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947 by Sociéte Belge de l'Azote et des Produits Chimiques du Marly; [6] Labaz developed benziodarone in 1957.
Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), is a United States Supreme Court case in which the Court held that Amgen's two patent applications on cholesterol-lowering drugs failed to satisfy the enablement clause of §112 of the Patent Act, 35 U.S.C. § 112(a).
Andrew J. Davidson [110] [111] February 9, 2025 Jennifer B. Higgins [112] January 20, 2025 February 9, 2025 U.S. Customs and Border Protection; Commissioner of U.S. Customs and Border Protection: Rodney Scott [113] Awaiting Senate Confirmation Pete R. Flores: January 20, 2025 Deputy Commissioner of U.S. Customs and Border Protection: John ...
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...
At Sanofi, leveraging AI to empower drug discovery and development is having a major impact. Our key AI models in small-molecule drug discovery are achieving more than 80% prediction accuracy ...
The first results of Sanofi’s OpenAI collaboration should be in by the end of 2024 and will most likely take the form of AI-generated first drafts of FDA documents. The results of the more ...
In November 2015, Sanofi announced its 2020 Strategic Plan that implies reshaping its activities into 3 portfolios: Diabetes, cardiovascular, and vaccines. [11] In May 2016, Olivier Brandicourt announced a reshuffle in the company's management, in line with the 2020 Strategic Plan. [12]
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.